



August 4th, 2023
ARCALIS Inc.

Notice of Completion of New mRNA Drug Substance Plant

ARCALIS Inc. (headquartered in Minamisoma City, Fukushima Prefecture; hereinafter "ARCALIS") is pleased to announce that its new mRNA Drug Substance Plant (hereinafter "NEW PLANT") under construction in Minamisoma City, Fukushima Prefecture was completed on July 31st, 2023, and a completion ceremony was held today, August 4th, 2023.

The NEW PLANT will meet the current Good Manufacturing Practice (cGMP) standards and has been equipped with the world's most advanced manufacturing and quality control systems. We are committed to meeting a variety of customers' demands.

【Description】

Name	ARCALIS Minamisoma Drug Substance Plant
Address	320-20 Kawauchisako, Shimoota aza, haramachi, Minamisoma, Fukushima, 975-0041
Structure	Steel frame, 5 floor, seismically isolated (36 meters)
Building Area	1933 m ²
Total floor space	7252 m ²
Outline of Plant Facilities	Equipped with the manufacturing facilities necessary to produce mRNA, a cutting-edge pharmaceutical product, for overseas use in compliance with cGMP
Manufacturing Items	mRNA and LNP in bulk
Production Capability	Up to 5 kg of Drug Substance per year in bulk
Estimated launch date of full-scale operation	August 2023
Construction, design and management in charge	Obayashi Corporation

About ARCALIS <https://corp.arcalis.co.jp/en>

ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization ("CDMO"), jointly established by Axcelead, Inc. (President & CEO, Yoshinori Ikeura, hereafter, Axcelead) and Arcturus Therapeutics, Inc. (NASDAQ: ARCT/hereafter, Arcturus). ARCALIS aims to develop the world's first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including pharmaceutical companies, biotech companies, and academic




institutes worldwide. The new facility in the city of Minamisoma (Fukushima Prefecture) is equipped with state-of-the-art manufacturing and quality control systems that meet the cGMP standards for pharmaceuticals.

1. NEW PLANT



2. Future Vision of Minamisoma Plant



② mRNA Drug Product Plant
(Scheduled completion of construction 2.2026)

① mRNA Drug Substance Plant
(Completion on July 31st, 2023)